CD4, UGT2B7, and CYP3A4 were selected as the potential diagnostic biomarkers of non-alcoholic fatty liver disease–hepatocellular carcinoma. Here, CYP3A4 is linked to metabolic dysfunction-associated steatotic liver disease.